ملخص
Abstract: Background: Clexane is used in pregnant women (PW) to minimize placental blood clotting (PBC) and
fetal danger. Standard coagulation tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), and
international normalized ratio (INR) are critical for anticoagulant medication optimization. As a result, the study’s goal was
to evaluate the efficacy of clexane as well as adherence to the American Heart Association’s recommended limits for routine
coagulation tests. Methods: The study included forty normal PW as controls and forty PW with PBC as patients from AlMafraq Hospital in Jordan. Patients were administered daily subcutaneous injections of 40 mg of clexane as an anticoagulant,
in conjunction with a daily 75 mg aspirin regimen. During the first trimester, 5 ml of venous blood were drawn from each
participant. The PT, INR and APTT were measured. This assessment also considered variables including plasma fibrinogen
concentration (PFC), age, body mass index (BMI), blood type, and fetal gender. Results: The mean age ± SD were 29.6
± 6.2 for the patient group and 28.3 ± 5.9 years for the control group. The changes in PT, INR, APTT and PFC between
the control and patient groups were statistically significant independent of mother’s age, BMI, baby gender, or blood type.
Patients displayed inadequate anticoagulation with an INR of 0.8, falling below the recommended therapeutic range of 2-3
for anticoagulant treatment. Surprisingly, by the end of the clinical study, all patients under investigation had safely delivered
their babies without difficulties. Conclusion: The observed rise in fibrinogen levels among patients may contribute to PBC
formation, necessitating further investigation. Evaluation of the safety and efficacy of a combined 40 mg Clexane and 75 mg
aspirin regimen in PW from the Al-Mafraq region, Jordan, is warranted
fetal danger. Standard coagulation tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), and
international normalized ratio (INR) are critical for anticoagulant medication optimization. As a result, the study’s goal was
to evaluate the efficacy of clexane as well as adherence to the American Heart Association’s recommended limits for routine
coagulation tests. Methods: The study included forty normal PW as controls and forty PW with PBC as patients from AlMafraq Hospital in Jordan. Patients were administered daily subcutaneous injections of 40 mg of clexane as an anticoagulant,
in conjunction with a daily 75 mg aspirin regimen. During the first trimester, 5 ml of venous blood were drawn from each
participant. The PT, INR and APTT were measured. This assessment also considered variables including plasma fibrinogen
concentration (PFC), age, body mass index (BMI), blood type, and fetal gender. Results: The mean age ± SD were 29.6
± 6.2 for the patient group and 28.3 ± 5.9 years for the control group. The changes in PT, INR, APTT and PFC between
the control and patient groups were statistically significant independent of mother’s age, BMI, baby gender, or blood type.
Patients displayed inadequate anticoagulation with an INR of 0.8, falling below the recommended therapeutic range of 2-3
for anticoagulant treatment. Surprisingly, by the end of the clinical study, all patients under investigation had safely delivered
their babies without difficulties. Conclusion: The observed rise in fibrinogen levels among patients may contribute to PBC
formation, necessitating further investigation. Evaluation of the safety and efficacy of a combined 40 mg Clexane and 75 mg
aspirin regimen in PW from the Al-Mafraq region, Jordan, is warranted
| اللغة الأصلية | English |
|---|---|
| رقم المقال | 3 |
| الصفحات (من إلى) | 83 |
| عدد الصفحات | 91 |
| دورية | Azerbaijan Pharmaceutical and Pharmacotherapy Journal |
| مستوى الصوت | 22 |
| رقم الإصدار | 3 |
| حالة النشر | Published - ديسمبر 1 2023 |